NCT Number: NCT05219500
Phase: Phase 2
Trial Summary: The treatment regimen will consist of 4 doses of 225Ac-PSMA- – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Fusion Pharmaceuticals Inc.
Acronym: TATCIST
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives